Published online 1 December 2009
Haematologica, Vol 94, Issue 12, 1708-1713 doi:10.3324/haematol.2009.011064
Copyright © 2009 by Ferrata Storti Foundation

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Chiecchio, L. PubMed PubMed Citation Articles by Chiecchio, L.

Monoclonal Gammopathies

Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context

Laura Chiecchio¹, Gian Paolo Dagrada¹, Ashraf H. Ibrahim¹, Elizabet Dachs Cabanas¹, Rebecca K.M. Protheroe¹, David M. Stockley¹, Kim H. Orchard^2,3, Nicholas C.P. Cross¹, Christine J. Harrison⁴, Fiona M. Ross¹ on behalf of the UK Myeloma Forum

¹ Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Human Genetics Division, University of Southampton, Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, Wilts
² Department of Haematology, Southampton University Hospital NHS Trust, Southampton General Hospital, Southampton
³ Cancer Sciences Division, University of Southampton, Southampton
⁴ Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK

Correspondence: Laura Chiecchio, Myeloma Cytogenetics Group, Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, Wilts SP2 8BJ, UK. E-mail: laura.chiecchio{at}salisbury.nhs.uk

Background: Multiple myeloma, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma harbor common chromosomal abnormalities but the prevalence and relative association of aberrations in these diagnostic groups remains controversial. We investigated these aspects in a large series of patients.

Design and Methods: Chromosome 13 deletion (13), deletion of TP53, ploidy status and immunoglobulin heavy chain (IgH) translocations were evaluated by fluorescence in situ hybridization in patients with monoclonal gammopathy of undetermined significance (n=189), smoldering multiple myeloma (n=127) and multiple myeloma (n=400).

Results: Overall, 13 (25%, 34% and 47%), 16q23 deletions (6%, 8% and 21%) and 17p13 deletions (3%, 1% and 10%) were less frequent in patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma than in those with multiple myeloma. When distinct genetic groups were considered, no differences in the prevalence of 13 were found with t(4;14)(p16;q32) and t(14;16)(q32;q23) among the three diagnostic groups; in contrast 13 was rarer in t(11;14)(q13;q32) in patients with monoclonal gammopathy (1/28) and smoldering myeloma (2/13) than in those with multiple myeloma (40%). Similar results were seen for the few t(6;14)(p21;q32) cases: 0/3 patients with monoclonal gammopathy or smoldering myeloma had the 13, whereas 4/6 (67%) patients with multiple myeloma and this translocation also had the deletion. In multiple myeloma patients with both an IgH translocation and 13, the proportions of cells affected by the two abnormalities were similar, as was the case for t(4;14) and t(14;16) monoclonal gammopathy patients positive for 13. In contrast, in monoclonal gammopathy patients with t(14;20)(q32;q11), the translocation was present in almost all cells, while the 13 was present in only a sub-population.

Conclusions: These results indicate that the presence and time of occurrence of 13 depends on the presence of specific concurrent abnormalities. The observation that 13 was extremely rare in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma with translocations directly involving cyclin D genes (CCND1 and CCND3) suggest a possible role of 13 in the progression of the disease specifically in these genetic sub-groups. (clinicaltrials.gov identifier: ISRCTN 68454111; UKCRN ID 1176).

Key words: deletion 13, plasma cell dyscrasias, genetic context.